carbapenems has been researched along with beta-lactams in 332 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (beta-lactams) | Trials (beta-lactams) | Recent Studies (post-2010) (beta-lactams) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 7,579 | 179 | 3,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (1.81) | 18.7374 |
1990's | 10 (3.01) | 18.2507 |
2000's | 92 (27.71) | 29.6817 |
2010's | 171 (51.51) | 24.3611 |
2020's | 53 (15.96) | 2.80 |
Authors | Studies |
---|---|
Gotoh, N; Nishino, T | 1 |
Hoban, DJ | 1 |
Livermore, DM; Yang, Y | 1 |
Chin, NX; Neu, HC | 1 |
Hirata, T; Sawai, T; Yamaguchi, A | 1 |
Andrews, JM; Danks, G; Wise, R | 1 |
Amano, S; Ezaki, N; Inouye, S; Ito, T; Kojima, M; Kondo, Y; Miyado, HS; Nida, T; Niwa, T; Ohba, K; Sezaki, M; Shomura, T; Yamada, Y | 1 |
Brughera, M; Dayan, AD; Iatropoulos, MJ; Mazue, G; Newman, AJ; Scampini, G | 1 |
Gutmann, L; Kitzis, MD; Zhou, XY | 1 |
Matsumura, N; Minami, S; Mitsuhashi, S | 1 |
Verbist, L; Verhaegen, J | 1 |
Babini, GS; Livermore, DM; Yuan, M | 1 |
Bycroft, BW; McGowan, SJ; Salmond, GP | 1 |
Biedenbach, DJ; Gales, AC; Jones, RN; Lewis, MT; Mathai, D; Yamaguchi, K | 1 |
Hikida, M; Igarashi, A; Itahashi, K; Kitamura, M; Shiba, T | 1 |
Matsuda, K; Matsumoto, S; Matsumoto, Y; Sasaki, H; Takasugi, H; Yoshida, Y | 1 |
Nishino, T; Oh, T; Okuda, J; Otsuki, M | 1 |
Gotoh, N; Nishino, T; Okamoto, K | 1 |
Stock, I; Wiedemann, B | 1 |
Odenholt, I | 1 |
Anzic, B; Copar, A; Mesar, T; Prevec, T; Selic, L; Solmajer, T; Vilar, M | 1 |
Ashwood, MS; Brands, KM; Cameron, M; Conrad, KM; Cottrell, IF; Davies, AJ; Dolling, UH; Houghton, PG; Jobson, RB; Kennedy, DJ; Pipik, B; Reamer, RA; Reider, PJ; Williams, JM | 1 |
Goldstein, EJ | 2 |
Armstrong, SH; Hilliard, NJ; Johnson, CN; Quarles, S; Waites, KB | 1 |
Amicosante, G; Colì, A; Docquier, JD; Lombardi, G; Luzzaro, F; Perilli, M; Riccio, ML; Rossolini, GM; Toniolo, A | 1 |
Livermore, DM; Scott, GM; Sefton, AM | 1 |
Isaacs, RD; Shah, PM | 1 |
Abe, T; Bonomo, RA; Knox, JR; Mansour, TS; Nukaga, M; Venkatesan, AM | 1 |
Chambers, HF; Katayama, Y; Zhang, HZ | 1 |
Birk, K; Deutsch, P; Holland, S; Majumdar, A; Mistry, G; Muckow, J; Musson, DG; Rogers, JD; Sciberras, D; Xi, L | 1 |
Bert, F; Branger, C; Lambert-Zechovsky, N | 1 |
Hammond, ML | 1 |
Calvo, F; Canduela, MJ; Gallego, L; Martín, G; Pujana, I; Sevillano, E; Umaran, A | 1 |
Holland, S; Lin, JH; Majumdar, A; Mistry, G; Musson, D; Sahly, Y; Singh, R; Waldman, S; Wong, BK; Xu, X; Yu, S | 1 |
Arakawa, Y; Doi, Y; Kubota, T; Shibata, N; Wachino, J; Yagi, T; Yamane, K | 1 |
Cars, O; Gustafsson, I | 1 |
Mi, ZH; Wang, CX | 1 |
Ariza, J; Ayats, J; Borraz, C; Cabellos, C; Corbella, X; Doménech, A; Gudiol, F; Montero, A; Tubau, F | 1 |
Lartigue, MF; Nordmann, P; Poirel, L | 1 |
Bornand, JE; Fonseca, S; Garbino, J; Sax, H; Uçkay, I | 1 |
Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
Huang, ST; Ko, WC; Lee, HC; Lee, NY; Liu, KH; Yan, JJ | 1 |
Mori, M | 1 |
Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
Livermore, DM; Mushtaq, S; Warner, M | 1 |
Embil, JM; Gin, A; Hoban, DJ; Johanson, C; Noreddin, A; Vercaigne, L; Zhanel, GG | 1 |
Everson, L; Fineran, PC; Hughes, K; Salmond, GP; Slater, H | 1 |
Majiduddin, FK; Palzkill, T | 1 |
Deters, M; Kaever, V; Koal, T; Resch, K | 1 |
Caines, ME; Kershaw, NJ; Schofield, CJ; Sleeman, MC | 1 |
Avlamis, A; Katsandri, A; Legakis, NJ; Pantazatou, A; Papaparaskevas, J | 1 |
Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
Chen, WH; Hsueh, PR; Luh, KT | 1 |
Dalhoff, A; Echols, R; Janjic, N | 1 |
Biedenbach, DJ; Huynh, HK; Jones, RN | 1 |
Campomanes, P; Menéndez, MI; Sordo, TL | 1 |
Chuang, YC; Walther-Rasmussen, J; Yu, WL | 1 |
Falagas, ME; Horianopoulou, M; Kanellopoulou, M; Lambropoulos, S; Legakis, NJ; Tsakris, A | 1 |
Hernández, JR; Martínez-Martínez, L; Pascual, A; Romero, L; Velasco, C | 1 |
Bernander, S; Ericson, E; Fraenkel, CJ; Larsson, P; Melhus, A; Rydberg, J; Törnqvist, E; Ullberg, M | 1 |
Holzgrabe, U | 1 |
Sendzik, J; Stahlmann, R | 1 |
Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
Bronze, MS; Cooper, TW; Gibbs, WJ; Greenfield, RA | 2 |
Fraser, VJ; Fridkin, SK; Kollef, MH; Merz, LR; Warren, DK | 1 |
Dallow, JW; Hill, RL; Livermore, DM; Palepou, MF; Pike, R; Ward, ME; Warner, M; Woodford, N | 1 |
Falagas, ME; Manta, KG; Siempos, II; Vardakas, KZ | 1 |
Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
Bauer, F; Benca, J; Grey, E; Huttova, M; Kovac, M; Ondrusova, A; Rudinsky, B; Sramka, M | 1 |
Bauer, F; Benca, J; Beno, P; Huttova, M; Kisac, P; Kovac, M; Ondrusova, A; Rudinsky, B; Sramka, M | 1 |
Allali, S; Kernbaum, S; Naas, T; Nordmann, P | 1 |
Chen, M; Guo, P; Sun, H; Wang, H; Xu, Y; Yang, Q; Zhu, Y | 1 |
Lister, PD | 1 |
Bishara, J; Lishtzinsky, Y; Madar-Shapiro, L; Ofir, O; Samra, Z | 1 |
Mikamo, H; Shinagawa, N; Takesue, Y; Takeyama, H; Tanaka, K; Taniguchi, M; Watanabe, K; Yokoyama, T | 1 |
Cuzon, G; Demachy, MC; Naas, T; Nordmann, P | 1 |
Yoshida, A | 1 |
Nicolau, DP | 1 |
Livermore, DM | 1 |
Shah, PM | 2 |
Fritsche, TR; Jones, RN; Sader, HS | 1 |
Ip, M; Kei, HW; Lau, WC; Lee, N; Marasinghe, T; Wong, KY; You, JH | 1 |
Bush, K; Davies, TA; Flamm, RK; Shang, W | 2 |
Fukumoto, A; Hanaki, H; Kim, YP; Omura, S; Shiomi, K; Tomoda, H | 1 |
Joseph, J; Rodvold, KA | 1 |
Cai, JC; Chen, GX; Zhang, R; Zhou, HW | 1 |
Gülmez, D; Hascelik, G; Kocagoz, S; Livermore, DM; Metan, G; Mushtaq, S; Palepou, MF; Uzun, O; Woodford, N; Yakupogullari, Y | 1 |
Ida, T; Kato, Y; Maebashi, K; Sanbongi, Y; Takahata, S | 1 |
Baba, N; Gomi, S; Ohsawa, F; Takeuchi, Y; Watanabe, T; Yamada, M | 1 |
Aybey, AD; Dinleyici, EC; Durmaz, G; Erben, N; Kiremitci, A; Usluer, G; Yargic, ZA | 1 |
Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F | 1 |
Akita, H; Chiba, N; Hasegawa, K; Iwata, S; Nonoyama, M; Sato, Y; Sunakawa, K; Ubukata, K | 1 |
Bogaerts, P; Cuzon, G; Glupczynski, Y; Huang, TD; Naas, T; Nordmann, P | 1 |
Basso, M; Costa, SF; Gobara, S; Gomez, LB; Levin, AS; Oshiro, I; Paez, JG; Spadão, F | 1 |
Blanchet, B; Chhun, S; Jullien, V; Lanternier, F; Legrand, T; Pons, G; Rey, E; Zahar, JR | 1 |
Carey, PR; Kalp, M | 1 |
Dunne, WM; Fraser, VJ; Frye, JG; Marschall, J; Tibbetts, RJ; Warren, DK | 1 |
Haldorsen, B; Lundblad, EW; Samuelsen, O; Simonsen, GS; Sundsfjord, A | 1 |
Harada, S; Ishii, Y; Yamaguchi, K | 1 |
Lortholary, O; Martin, C; Nordmann, P; Plesiat, P; Potel, G; Zahar, JR | 1 |
Clarke, MJ; Edwards, SJ; Welton, NJ; Wordsworth, S | 1 |
Boo, TW; Crowley, B | 1 |
Brémont, S; Conroy, MC; Courvalin, P; Lambert, T; Moubareck, C | 1 |
Badal, RE; Bouchillon, SK; Hackel, M; Hawser, SP; Hoban, DJ; Johnson, JL | 1 |
Aggoune-Khinache, N; Bonnet, R; Delmas, J; Naim, M; Robin, F | 1 |
Cattoir, V; Daurel, C | 1 |
Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
Eagye, KJ; Nicolau, DP | 2 |
Blanchard, JS; Fan, F; Tremblay, LW | 1 |
Du, X; Ji, S; Li, L; Qi, Y; Shen, P; Wei, Z; Yu, Y | 1 |
dos Santos, RP; Goldani, LZ; Jacoby, T | 1 |
Blanca, M; Torres, MJ | 1 |
Ko, WC; Lee, CC; Wu, JJ; Yan, JJ; Yang, FC | 1 |
Benhamou, D; Figueiredo, S; Mugnier, P; Nordmann, P; Poirel, L; Seifert, H | 1 |
Chmielewski, M; Furman, B; Grzeszczyk, B; Kozioł, A; Staszewska-Krajewska, O | 1 |
Fisher, JF; Llarrull, LI; Mobashery, S; Testero, SA | 1 |
Cai, J; Liu, J; Wu, D | 1 |
Ahmed-Bentley, J; Peirano, G; Pitout, JD; Woodford, N | 1 |
Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
Hsueh, PR; Huang, WH; Ko, WC; Lee, NY; Tsui, KC | 1 |
Engler, C; Harris, P; Norton, R | 1 |
Dihmess, A; Evans, A; Fiorenza, M; Graffunder, E; Harrington, S; Lodise, TP; Martis, P; Masoud, R; McNutt, LA; Patel, N; Woo, B | 1 |
Bergerová, T; Hrabák, J; Urbásková, P; Zemlicková, H | 1 |
Curran, MD; Ludlam, HA; Shet, VG; Swayne, RL; Woodford, N | 1 |
Gastal, SL; Goldani, LZ; Gorniak Lovatto, C; Jacoby, T; Konkewicz, L; Kuplich, NM; Lisboa, T; Nagel, FM; Pires dos Santos, R; Pires Machado, D; Pires, MR | 1 |
Bordon, JM; Clark, RB; Karlowsky, JA; Master, RN; Ramirez, J | 1 |
Beović, B; Cizman, M; Kreft, S; Seme, K | 1 |
Bonomo, RA; Endimiani, A; Papp-Wallace, KM; Taracila, MA | 1 |
Sakata, H | 1 |
Cook, PP; Gooch, M; Rizzo, S | 1 |
Carmeli, Y; Crank, CW; Goff, DA; Goldstein, EJ; Graber, CJ; Lima, AL; Nicolau, DP | 1 |
Chang, SC; Chen, WC; Chen, YC; Hu, FC; Wang, JL; Wu, UI; Yang, CS | 1 |
Antunes, NT; Frase, H; Toth, M; Vakulenko, SB | 1 |
López, M; Martín, C; Rojo-Bezares, B; Sáenz, Y; Torres, C | 1 |
Bonnin, RA; Boulanger, A; Kaase, M; Nordmann, P; Poirel, L; Schrenzel, J | 1 |
Farbman, L; Leibovici, L; Paul, M; Yahav, D | 1 |
Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
Bourigault, C; Caroff, N; Corvec, S; Crémet, L; Guillouzouic, A; Juvin, ME; Lepelletier, D; Reynaud, A | 1 |
González, LJ; Vila, AJ | 1 |
Adnan, S; Kumar, S; Li, J; Lipman, J; Paterson, DL; Roberts, JA; Rudd, M | 1 |
Chiu, CH; Su, LH; Wu, TL | 1 |
DiPardo, BJ; Phelan, RM; Townsend, CA | 1 |
Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
Cai, Y; Kwa, AL; Lee, W; Tan, TT; Tan, TY; Tang, S; Teo, J | 1 |
Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
Aleo, A; Bonura, C; Brunelli, T; Degl'Innocenti, R; Fasciana, T; Mammina, C; Nastasi, A; Pesavento, G | 1 |
Alves, MS; Araújo, S; Azevedo, JS; Chouchani, C; Correia, A; Henriques, IS; Pereira, A | 1 |
Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Ho, MW; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Tang, HJ; Toh, HS; Wang, JH; Yu, KW | 1 |
Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 2 |
Bebrone, C; Bennink, S; Bogaerts, P; Delbrück, H; Galleni, M; Glupczynski, Y; Hoffmann, KM; Kupper, MB; Rezende de Castro, R | 1 |
McDougall, DA; Morton, AP; Playford, EG | 1 |
Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
de la Peña, S; Fernández-Soria, VM; Gómez-Gil, R; Gomez-Puertas, P; López-Camacho, E; Lusa-Bernal, S; Mingorance, J; Ramos-Ruiz, R; Ruiz-Carrascoso, G; Wesselink, JJ | 1 |
Barszcz, B; Cielecka-Piontek, J; Lewandowska, K; Paczkowska, M | 1 |
Crandon, JL; Hagihara, M; Nicolau, DP; Urban, CM | 1 |
Belmonte, O; Boyer, S; Camiade, S; Nordmann, P; Poirel, L; Potron, A; Rondinaud, E | 1 |
Patel, V; Rodriguez, C; Singhal, T; Soman, R; Trivedi, M | 1 |
Falagas, ME; Kapaskelis, A; Tansarli, GS; Vardakas, KZ | 1 |
Berendsen, BJ; Gerritsen, HW; Lameris, S; Nielen, MW; Stolker, AA; van Sebille, R; Wegh, RS | 1 |
Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
Chen, L; Liu, S; Lu, Z; Schwarz, S; Si, W; Wang, XM; Yu, S; Zhang, RM; Zhang, WJ | 1 |
Debets-Ossenkopp, Y; Murk, JL; Vainio, S; van Doorn-Schepens, M; Vandenbroucke-Grauls, C; Wilhelm, A | 1 |
Falagas, ME; Kapaskelis, A; Karageorgopoulos, DE; Tansarli, GS | 1 |
Crandon, JL; Hagihara, M; Nicolau, DP; Urban, C | 1 |
Adler, M; Cars, O; Löwdin, E; Sandegren, L; Tängdén, T | 1 |
Chmielewski, M; Furman, B; Grzeszczyk, B; Mucha, Ł; Staszewska-Krajewska, O; Stecko, S | 1 |
Falagas, ME; Ikawa, K; Tansarli, GS; Vardakas, KZ | 1 |
Gupta, N; Rodrigues, C; Shetty, A; Soman, R | 1 |
Caio, C; Ceccarelli, G; Falcone, M; Giordano, A; Mezzatesta, ML; Stefani, S; Venditti, M | 1 |
Castanheira, M; Deshpande, LM; Farrell, SE; Jones, RN; Mendes, RE | 1 |
Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 3 |
Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
Bodro, M; Boix, L; Calvo, M; Carratalà, J; Contra, A; Domingo-Domenech, E; Garcia-Vidal, C; Gudiol, C; Tubau, F | 1 |
Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
Bethel, CR; Bonomo, RA; Bou, G; Desarbre, E; Fernández, A; Gatta, JA; Hujer, AM; Mallo, S; Page, MG; Papp-Wallace, KM; Smith, KM; Taracila, MA; Xu, Y | 1 |
Chen, Z; Kang, M; Li, D; Tao, C; Wang, T; Xie, Y | 1 |
Farrell, R; Kopacz, J; Mariano, N; Piracha, N; Prasad, N; Segal-Maurer, S; Shakil, J; Tarasuk, A; Urban, C; Wang, G | 1 |
Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Tada, T | 1 |
Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
Barth, AL; da Silva, RC; Dalarosa, MG; Falci, DR; Luz, DI; Magagnin, CM; Ribeiro, VB; Rozales, FP; Sampaio, JM; Vieira, FJ; Zavascki, AP | 1 |
Kim, HJ; Kim, MJ; Lee, SE; Sohn, JW; Yang, KS; Yoon, YK | 1 |
Badal, RE; Biedenbach, DJ; Bouchillon, SK; Hackel, M; Hoban, DJ; Nga, TT; Phuong, DM; Phuong, NT; Phuong, TT | 1 |
Chang, M; Fishovitz, J; Hermoso, JA; Mobashery, S | 1 |
Bhattacharyya, RP; Hung, DT; Wivagg, CN | 1 |
Amicosante, G; Bellio, P; Bottoni, C; Brisdelli, F; Celenza, G; Di Pietro, L; Mancini, A; Perilli, M; Sabatini, A; Segatore, B | 1 |
Danishuddin, M; Faheem, M; Khan, A; Khan, AU | 1 |
Hong, MK; Jeon, JH; Jo, JY; Kang, LW; Karim, AM; Kim, JH; Ko, KS; Lee, JH; Lee, JJ; Lee, SH; Park, KS | 1 |
Black, DJ; Frase, H; Smith, CA; Stewart, NK; Vakulenko, SB | 1 |
Bai, KJ; Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsu, CW; Hsueh, PR; Jean, SS; Ko, WC; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
Daitch, V; Farbman, L; Lador, A; Leibovici, L; Paul, M; Tredler, Z; Zusman, O | 1 |
Lastra, Vde L; Pinto, ME; Rivas, LM; Silva, F; Ulloa, MT; Vidal, M | 1 |
Barreto, JN; Tosh, PK; Vasoo, S | 1 |
Carlson, EE; Kocaoglu, O; Tsui, HC; Winkler, ME | 1 |
Amicosante, G; Bottoni, C; Celenza, G; Colapietro, M; Compagnoni, C; Marcoccia, F; Maturo, MG; Perilli, M; Sabatini, A; Segatore, B | 1 |
Eslami, G; Langaee, T; Rafati, M; Rafiei, A; Rezai, MS; Salehifar, E; Shafahi, K | 1 |
Blaszczyk, AJ; Booker, SJ; Buller, AR; Grove, TL; Lloyd, EP; Marous, DR; Moshos, KA; Townsend, CA | 1 |
Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U | 1 |
Artichowicz, W; Fudala-Ksiazek, S; Kotlarska, E; Luczkiewicz, A; Tarasewicz, K | 1 |
Anupurba, S; Banerjee, T; Filgona, J | 1 |
Cprek, JB; Gallagher, JC | 1 |
Arora, R; Chakotiya, AS; Chawla, R; Goel, R; Narula, A; Sharma, RK; Tanwar, A; Thakur, P | 1 |
Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
Cipolla, A; D'Abramo, A; De Angelis, M; Favaro, M; Ferretti, G; Gizzi, F; Iannetta, M; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Vullo, V | 1 |
Akova, M; Almela, M; Almirante, B; Bermejo, J; Bonomo, RA; Bou, G; Calbo, E; Carmeli, Y; Cisneros, JM; García-Vázquez, E; Gasch, O; Giamarellou, H; Gracia-Ahulfinger, I; Gutiérrez-Gutiérrez, B; Hamprecht, A; Hsueh, PR; Lowman, W; Martínez-Martínez, L; Mora-Rillo, M; Oliver, A; Origüen, J; Pascual, A; Paterson, DL; Peña, C; Pérez, F; Pintado, V; Pitout, J; Prim, N; Rodríguez-Baño, J; Schwaber, MJ; Tacconelli, E; Tumbarello, M; Venditti, M; Viale, P | 1 |
Damer, KM; Roman, C; Solh, T | 1 |
Centis, R; D'Ambrosio, L; Dore, S; Esposito, S; Migliori, GB; Sotgiu, G; Spanevello, A; Tiberi, S | 1 |
Aktaş, Z; Akyön, Y; Aşçı Toraman, Z; Ay, S; Ayaş, R; Aydemir, Ş; Aydın, F; Bakıcı, Z; Bayramoğlu, G; Baysallar, M; Büyüktaş, A; Çağatay, M; Çakar, A; Çelik, C; Çöplü, N; Dündar, D; Erçal, BD; Güdücüoğlu, H; Gülay, Z; Günaydın, M; Gür, D; Hasdemir, U; Karatuna, O; Kayacan, Ç; Kılıç, A; Kılıç, H; Öğünç, D; Özhak Baysan, B; Parlak, M; Tünger, A; Yanık, K; Zer, Y | 1 |
Akova, M; Almela, M; Almirante, B; Bermejo, J; Bonomo, RA; Bou, G; Calbo, E; Carmeli, Y; de Cueto, M; Gasch, O; Giamarellou, H; Gutiérrez-Gutiérrez, B; Hamprecht, A; Hernández, A; Hsueh, PR; Lowman, W; Martínez-Martínez, L; Molina, J; Mora-Rillo, M; Natera, C; Oliver, A; Origüen, J; Pascual, A; Paterson, DL; Peña, C; Pérez, F; Pérez-Galera, S; Pintado, V; Pitout, J; Prim, N; Rodríguez-Baño, J; Salamanca, E; Schwaber, MJ; Souli, M; Tacconelli, E; Tumbarello, M; Venditti, M; Viale, P | 1 |
Hu, Q; Hu, Y; Lin, X; Lv, H; Xu, X; Zhang, R | 1 |
Burgers, PC; Dekker, LJ; Goessens, WH; Kostzrewa, M; Luider, TM; Monteferrante, CG; Peer, M; Sparbier, K; Sultan, S; Ten Kate, MT | 1 |
Arai, K; Kashiwa, M; Nagano, N; Saito, R; Yamada, K | 1 |
Furuyama, T; Hanson, ND; Ishii, Y; Nonomura, H; Shimizu-Ibuka, A | 1 |
Essaied, W; Garrouste-Orgeas, M; Ruckly, S; Schwebel, C; Timsit, JF; Weiss, E; Zahar, JR | 1 |
Chmielewski, M; Furman, B; Pieczykolan, M; Staszewska-Krajewska, O | 1 |
Dinic, M; Kocic, B; Mitic, R; Mladenovic-Antic, S; Petrovic, J; Randjelovic, G; Velickovic-Radovanovic, R | 1 |
Badal, RE; Biedenbach, DJ; Giao, PT; Hung Van, P; Phuong, DM; Su Minh Tuyet, N; Thi Thanh Nga, T; Vu Trung, N | 1 |
Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL | 1 |
Bontron, S; Nordmann, P; Poirel, L | 1 |
Li, M; Skalweit, MJ | 1 |
Leonard, DA; Peng, JW; Staude, MW | 1 |
Bomfim, MR; Coqueiro, MM; de Jesus Gomes Turri, R; Marques, AC; Marques, SG; Monteiro, AS; Monteiro, SG; Monteiro-Neto, V; Ribeiro, PC; Santos, SG | 1 |
Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
Schneider, G; Schnell, R; Steiner, EM | 1 |
Biswal, S; Ghosh, AS; Issa, B; Kar, D; Kumar, G | 1 |
Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
Alp, E; Badal, R; Gulay, Z; Koksal, I; Korten, V; Lob, S; Mete, B; Mulazimoglu, L; Oguz, VA; Tabak, F; Unal, S; Yilmaz, G; Zarakolu, P | 1 |
Bhattacharjee, A; Chakravarty, A; Choudhury, NA; Dhar, D; Ingti, B; Maurya, AP; Paul, D | 1 |
Kwon, DH; Lee, S; Razqan, GS | 1 |
Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
Jitmuang, A; Kiratisin, P; Rattanaumpawan, P; Thamlikitkul, V; Werarak, P | 1 |
Fisher, S; Galanis, C; Gupta, C; Kaushik, A; Lamichhane, G; Parrish, N; Story-Roller, E | 1 |
D'Arcy, S; Doumith, M; Findlay, J; Hopkins, KL; Howe, R; Mather, B; Meunier, D; Mustafa, N; Pike, R; Woodford, N; Wootton, M | 1 |
Fakhar, Z; Govender, T; Honarparvar, B; Kruger, HG; Lamichhane, G; Maguire, GEM; Walker, RC | 1 |
Falagas, ME; Kofteridis, DP; Maraki, S; Mavromanolaki, VE; Perdikis, D; Samonis, G; Vardakas, KZ | 1 |
Basta, LAB; Bianchet, MA; Kumar, P; Lamichhane, G; Lloyd, EP; Mattoo, R; Pan, YH; Saavedra, H; Townsend, CA | 1 |
Brunelle, JL; Kaushik, A; Kumar, P; Lamichhane, G; Lloyd, EP; Mattoo, R; Townsend, CA | 1 |
Al-Ahmad, M; Rodriguez-Bouza, T | 1 |
Abdala, E; Akova, M; Álvarez, R; Cano, A; Carratalà, J; Cervera, C; Clemente, WT; Freifeld, A; Gómez, L; Gottlieb, T; Gudiol, C; Gurguí, M; Herrera, F; Maestro-de la Calle, G; Manzur, A; Martín-Dávila, P; Maschmeyer, G; Meije, Y; Montejo, M; Peghin, M; Rodríguez-Baño, J; Royo-Cebrecos, C; Ruiz-Camps, I; Sukiennik, TC; Tebe, C | 1 |
Al-Hasan, MN; Albrecht, HA; Bookstaver, PB; Hammer, KL; Justo, JA; Kohn, J; Nimmich, EB; Smith, TJ; Troficanto, C | 1 |
Andrews, B; Bifulco, N; Carter, NM; Chen, B; Comita-Prevoir, J; de Jonge, B; Durand-Réville, TF; Ehmann, DE; Gao, N; Giacobbe, RA; Guler, S; Huynh, H; Lahiri, S; McLaughlin, R; McLeod, SM; Miller, AA; Moussa, SH; Mueller, JP; Newman, JV; O'Donnell, J; Olivier, NB; Palmer, T; Shapiro, AB; Thresher, J; Tommasi, RA; Velez-Vega, C | 1 |
Antonelli, M; Arcadipane, A; Capitanio, G; Cutuli, SL; De Pascale, G; Di Carlo, D; Di Gravio, V; Di Stefano, R; Martucci, G; Montini, L; Panarello, G; Polidori, P; Spanu, T; Vallecoccia, MS | 1 |
Martin, NI; Tehrani, KHME | 1 |
Grant, M; Holt, S; Thompson-Brazill, KA | 1 |
Kim, JH; Kim, MJ; Kim, SB; Sohn, JW; Suh, JW; Yang, KS; Yoon, YK | 1 |
Achard, MES; Anderson, GJ; Djoko, KY; Hancock, SJ; Harris, PN; Lo, AW; McEwan, AG; Miraula, M; Mitić, N; Paterson, DL; Peters, KM; Phan, MD; Prombhul, S; Schembri, MA; Schenk, G; Shafer, WM; Sidjabat, HE; Walsh, TR | 1 |
Eumkeb, G; Evans, K; Hobbs, G; Nakouti, I; Teethaisong, Y | 1 |
Horvath, E; Kazmierczak, KM; Sahm, DF; Wise, MG; Young, K | 1 |
Gupta, S; Mukhopadhyay, C; Pathak, A; Prasad, KN; Rahman, M; Rai, RP; Singh, A; Singh, S | 1 |
Jett, R; Lopez, J; O'Donnell, JN; Rhodes, NJ; Scheetz, MH | 1 |
Keshri, V; Levasseur, A; Panda, A; Pontarotti, P; Raoult, D; Rolain, JM | 1 |
Li, Y; Liu, J; Liu, Y; Shen, L; Yu, J; Zhu, W | 1 |
Kamps, JJAG; Lohans, CT; Rabe, P; Schofield, CJ | 1 |
Kanehisa, M | 1 |
Bonnin, RA; Dabos, L; Fortineau, N; Iorga, BI; Jousset, AB; Naas, T; Retailleau, P; Zavala, A | 1 |
Guo, Q; Hu, F; Li, Y; Su, J; Wang, M; Wu, S; Xu, S | 1 |
Bertrand, X; Boyer, A; Coppry, M; Dubois, V; Dumartin, C; Jeanne-Leroyer, C; Noize, P; Rogues, AM | 1 |
Naber, KG; Wagenlehner, FME | 1 |
Galani, I; Giamarellou, H; Karaiskos, I; Souli, M | 1 |
Ammerman, NC; Kaushik, A; Kreiswirth, BN; Lamichhane, G; Lee, J; Martins, O; Nuermberger, EL; Parrish, NM | 1 |
Fukushima, Y; Hiyama, Y; Masumori, N; Nakajima, C; Sato, T; Shinagawa, M; Suzuki, Y; Takahashi, S; Yokota, SI | 1 |
Bobola, V; Forbes, W; Frazier, W; Joyner, ML; Manning, CC | 1 |
Li, WJ; Maruthupandy, M; Quero, F; Rajivgandhi, G; Veeramani, T | 1 |
Bragginton, EC; Colenso, CK; Hinchliffe, P; Hirvonen, VHA; Spencer, J; Takebayashi, Y; Tooke, CL | 1 |
Al-Bustan, SA; Alkhudhairy, MK; Alshadeedi, SMJ; Ghasemian, A; Mahmood, SS | 1 |
Alfonso, C; Berger, MA; Cejas, D; De Paulis, A; Elena, A; Fernández-Canigia, L; Guevara Nuñez, D; Gutkind, G; Magariños, F; Radice, M; Sevillano Platero, P | 1 |
Dean, CR; Ke, X; Lopez, SL; McEnroe, G; Ranjitkar, S; Reck, F; Zhu, Q | 1 |
Akata, K; Kawanami, T; Kido, T; Mukae, H; Muratani, T; Naito, K; Noguchi, S; Yamasaki, K; Yatera, K | 1 |
Jang, SM; Mueller, BA; Pai, MP; Shaw, AR | 1 |
DeShong, P; Ganapati, S; Nanayakkara, IA; Nguyen, HT; Watts, D; White, IM | 1 |
Higuita-Gutiérrez, LF; Jiménez-Quiceno, JN; Vargas-Alzate, CA | 1 |
Nishida, S; Ono, Y | 1 |
Caroline, C; Chien-Boon Lye, D; Choon-Kiat Tan, N; Ding, YY; Hsien-Xiong Lee, R; Lim, JP; Neo, HY; Pei-Ying Ho, E; Tan, KT; Wei-Han Ng, D | 1 |
Choi, J; Dantas, G; Das, S; Gandra, S; Green, SJ; Harazin, M; McElvania, E; Singh, KS; Thomson, RB | 1 |
Barth, AL; Basso, KB; Bonomo, RA; Boyce, JD; Bulitta, JB; Deveson Lucas, D; Drusano, GL; Jiao, Y; Kim, TH; Lang, Y; Lee, RE; Louie, A; Moya, B; Reeve, SM; Schweizer, HP; Shin, BS; Sutaria, DS; Tao, X; Zavascki, AP; Zhou, J | 1 |
Bostock, MJ; Fino, R; Kolonko, M; Mejdi-Nitiu, R; Meyer, H; Popowicz, GM; Sattler, M; Softley, CA; Zak, KM; Zhou, RX | 1 |
Craft, DW; England, MR; Hale, CM; Lesher, MD; Myers, DS; Wijetunge, DSS | 1 |
Carter, NM; McLeod, SM; Miller, AA; Moussa, SH; Mueller, JP; Shapiro, AB; Tommasi, R | 1 |
Bonsall, TJ; Miller, CL; Wilhelm, NB | 1 |
Berthomieu, D; De Luca, F; Docquier, JD; Feller, G; Galleni, M; Gavara, L; Gresh, N; Hernandez, JF; Legru, A; Marcoccia, F; Mercuri, PS; Nauton, L; Sannio, F; Sevaille, L; Tanfoni, S; Verdirosa, F | 1 |
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
Maquieira, Á; Morais, S; Peña-Mendizabal, E | 1 |
Kois, AK; Kuti, JL; Nicolau, DP | 1 |
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A | 1 |
Chen, L; Jiang, J; Li, X; Li, Y; Liang, X; Tang, X | 1 |
Gasparetto, J; Telles, JP; Tuon, FF; Zequinão, T | 1 |
Abdelraouf, K; Nicolau, DP; Reyes, S | 1 |
Abbaszadeh, F; Baradaran, B; Dehghani, L; Hasani, A; Rezaee, MA; Samadi Kafil, H; Vahhabi, A | 1 |
Bagheri, H; Dao, VT; Montastruc, JL; Nguyen, HA; Nguyen, KD; Vu, DH | 1 |
Arthur, M; Braud, E; Edoo, Z; Etheve-Quelquejeu, M; Fonvielle, M; Iannazzo, L; Riomet, M; Rusconi, F; Saidjalolov, S; Sallustrau, A; Taran, F | 1 |
Bonnin, RA; Dortet, L; Emeraud, C; Gonzalez, C; Iorga, BI; Naas, T; Oueslati, S; Rima, M | 1 |
Cho, HS; D'Souza, R; Kim, H; Lee, H; Nguyen, LP; Pinto, NA; Vu, TN; Yong, D | 1 |
Bhagwat, S; Joshi, P; Patel, M; Shrivastava, R | 1 |
Aoki, T; Komano, K; Kusano, H; Matsumoto, S; Oguma, T; Sato, J; Sato, T; Shibuya, S; Yamawaki, K; Yasuo, K; Yokoo, K | 1 |
Armstrong, T; Fenn, SJ; Hardie, KR | 1 |
Johns, ML; Klimko, CV; Sanders, JM | 1 |
Alquethamy, SF; Bauer, MJ; Beatson, SA; Blaskovich, MAT; Brouwer, S; Cork, AJ; De Oliveira, DMP; El-Deeb, IM; Forde, BM; Harbison-Price, N; Keller, N; Li, G; McDevitt, CA; McEwan, AG; Paterson, DL; Phan, MD; Roberts, JA; Schembri, MA; Steiner, B; von Itzstein, M; Walker, MJ; Zhang, B; Zuegg, J | 1 |
Aoki, T; Komano, K; Kusano, H; Matsumoto, S; Nakamura, R; Oguma, T; Sato, J; Sato, T; Shibuya, S; Yamawaki, K; Yokoo, K | 1 |
Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
Blaskovich, M | 1 |
Abaza, M; Aboubakr, M; Awad, D; Edris, S; Fouad, M; Hamad, A; Hussein, A; Nabil, M; Ramadan, H; Sabeq, I; Shama, S | 1 |
Anes, E; Catalão, MJ; Gomes, JP; Macedo, R; Miragaia, M; Nunes, A; Olivença, F; Pires, D; Silveiro, C | 1 |
Beer, M; Chudyk, EI; Jones, CA; Limb, MAL; Mulholland, AJ; Spencer, J; van der Kamp, MW | 1 |
Ju, F; Zhang, G; Zhang, Z | 1 |
Barata, RR; Brasiliense, DM; Camargo, DS; Carneiro, ICRS; Costa, CJS; Dutra, LMG; Lobato, A; Martins, WMBS; Souza, CO | 1 |
Alfandari, S; Bajolet, O; Blanchard, H; Colomb-Cotinat, M; Daniau, C; Dumartin, C; Lecuru, M; Simon, L | 1 |
Dartois, V; Dick, T; Negatu, DA; Zimmerman, MD | 1 |
Chen, DQ; Chen, EZ; Ling, JH; Liu, WT; Peng, C; Wang, LJ; Yang, L; Yuan, PB; Zhong, YX; Zhu, JH | 1 |
Buranapraditkun, S; Chongpison, Y; Klaewsongkram, J; Mongkolpathumrat, P; Palapinyo, S; Thantiworasit, P | 1 |
Gehlot, P; P, H | 1 |
Cabañero-Navalón, MD; Garcia-Bustos, V; Salavert Lletí, M | 1 |
Axelrod, P; Holaday, E; Mishkin, A; Motzer, AR | 1 |
Arimuthu, DA; Mazlan, SA; Shahar, S | 1 |
Cai, Y; Wang, J; Wang, Y; Xiao, Q; Xu, J; Zhang, H; Zhu, M | 1 |
Gatti, M; Pea, F | 1 |
Chen, L; He, XP; Hong, SJ; Hua, J; Jing, RC; Luo, XY; Xue, HW; Yuan, CY; Yue, Y | 1 |
Ambrose, PG; Bhavnani, SM; Conde, H; Cotroneo, N; Friedrich, LV; Jones, S; VanScoy, BD | 1 |
Crow, A; Dai, Y; Dowson, CG; Geisinger, E; Isberg, RR; Lloyd, AJ; Micelli, C; Raustad, N; Roper, DI | 1 |
Bonomo, RA; Calvopiña, K; Dmitrienko, GI; Hinchliffe, P; Mojica, MF; Rabe, P; Schofield, CJ; Spencer, J; Vila, AJ | 1 |
Chang, YH; Hsu, CK; Huang, PY; Lai, CC; Liu, TH; Tang, HJ; Tsai, YW; Wu, JY | 1 |
Duru, C; Ebruke, BE; Egah, R; Hanga, F; James, AO; Jibir, B; Medugu, N; Obaro, SK; Odili, V; Olanipekun, G; Olateju, EK; Tenover, FC; Tickler, IA | 1 |
Allel, K; Araos, R; Arias, CA; Conejeros, J; García, P; Lessa, FC; Martínez, JRW; McGovern, O; Munita, JM; Orellana Chea, C; Patel, TS; Peters, A; Riquelme-Neira, R; Rivas, L; Rojas, P; Spencer-Sandino, M; Undurraga, EA | 1 |
Caseris, M; Cohen, R; Dortet, L; Lorrot, M; Raymond, J; Toubiana, J | 1 |
56 review(s) available for carbapenems and beta-lactams
Article | Year |
---|---|
Bacterial production of carbapenems and clavams: evolution of beta-lactam antibiotic pathways.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clavulanic Acids | 1998 |
Ertapenem: a new carbapenem.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials, Phase II as Topic; Drug Evaluation; Ertapenem; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Lactams; Microbial Sensitivity Tests | 2001 |
Properties and potential of ertapenem.
Topics: Bacteria; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Drug Resistance, Bacterial; Ertapenem; Half-Life; Humans; Lactams | 2003 |
Ertapenem, the first of a new group of carbapenems.
Topics: Animals; beta-Lactams; Carbapenems; Clinical Trials as Topic; Cross Infection; Ertapenem; Humans; Lactams | 2003 |
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Carbapenems; Community-Acquired Infections; Ertapenem; Humans; Lactams | 2004 |
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
[Development of new synthetic method using organometallic complexes and an application toward natural product synthesis].
Topics: Acetylene; Alkaloids; Benzodiazepinones; beta-Lactams; Carbapenems; Carbon Dioxide; Carbon Monoxide; Catalysis; Chemistry, Organic; Cyclization; Ethylenes; Gases; Harringtonines; Homoharringtonine; Indole Alkaloids; Indoles; Nitrogen; Organometallic Compounds; Quinolines; Quinolizines; Strychnine | 2005 |
Ertapenem: review of a new carbapenem.
Topics: Animals; beta-Lactams; Carbapenems; Drugs, Investigational; Ertapenem; Humans; Lactams | 2005 |
Redefining penems.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Structure; Penicillins | 2006 |
Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Molecular Epidemiology; Taiwan | 2006 |
[Structure-activity relationships of penicillin G to tricyclic beta-lactams].
Topics: Bacteria; beta-Lactams; Carbapenems; Cephalosporins; Humans; Penicillin G; Penicillins; Structure-Activity Relationship | 2006 |
[Opposition to Ehrlich's paradigm of selective toxicity. Adverse effects of beta lactam antibiotics].
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Diarrhea; Drug Hypersensitivity; Enterocolitis, Pseudomembranous; Humans; Monobactams; Penicillins | 2006 |
Part II. Introduction to the beta-lactam antibiotics.
Topics: Administration, Oral; Anaphylaxis; Anti-Bacterial Agents; Bacteria; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cephalosporins; Cross Reactions; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Injections, Intravenous; Microbial Sensitivity Tests; Monobactams; Penicillins; Skin Tests; Time Factors | 2006 |
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aminoglycosides; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Fluoroquinolones; Humans; Immunocompetence; Intensive Care Units; Meropenem; Pneumonia, Bacterial; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiration, Artificial; Survival Rate; Thienamycins; Treatment Outcome | 2007 |
Part V. Other beta-lactam antimicrobials.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Humans; Monobactams | 2007 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
[Attention-getting cross infections: Extended-spectrum beta-lactamase-producing bacterial infections].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Proteus; Proteus Infections | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
Defining an extended-spectrum beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Escherichia coli; Gram-Negative Bacteria; Kinetics; Microbial Sensitivity Tests; Mutation | 2008 |
Parenteral carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Imipenem; Infusions, Parenteral; Meropenem; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
[Broad-spectrum beta-lactamases in Gram-negative bacteria].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Monobactams; Penicillins; Plasmids | 2008 |
Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Enterobacteriaceae Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests | 2008 |
Addressing the challenge of extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2009 |
[Update on antimicrobial chemotherapy].
Topics: Acetamides; Aminoglycosides; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Daptomycin; Doripenem; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; France; Humans; Linezolid; Lipoglycopeptides; Minocycline; Oxazolidinones; Penicillins; Pyrimidines; Teicoplanin; Tigecycline | 2010 |
The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Clavulanic Acids; Cross Reactions; Drug Hypersensitivity; Humans; Monobactams; Penicillins; Risk Factors; Skin Tests | 2010 |
The future of the β-lactams.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Monobactams | 2010 |
Carbapenems: past, present, and future.
Topics: Anti-Bacterial Agents; beta-Alanine; beta-Lactams; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Thienamycins | 2011 |
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Colistin: new lessons on an old antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2012 |
Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Diffusion; Drainage; Humans; Intraabdominal Infections; Metabolic Clearance Rate; Penicillins | 2012 |
Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pseudomonas aeruginosa | 2013 |
Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Hospital Costs; Humans; Methicillin-Resistant Staphylococcus aureus | 2013 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus.
Topics: Allosteric Regulation; beta-Lactams; Carbapenems; Cell Wall; Cephalosporins; Cross-Linking Reagents; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Models, Molecular; Molecular Structure; Penicillin-Binding Proteins; Penicillins; Peptide Synthases | 2014 |
Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Drug Therapy, Combination; Humans; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Infection Control | 2015 |
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Clinical Studies as Topic; Ertapenem; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Meropenem; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Healthcare-Associated Pneumonia; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Odds Ratio; Pseudomonas aeruginosa; Randomized Controlled Trials as Topic; Risk Factors; Staphylococcus aureus; Survival Analysis; Treatment Outcome | 2018 |
Roles of 2-oxoglutarate oxygenases and isopenicillin N synthase in β-lactam biosynthesis.
Topics: beta-Lactams; Carbapenems; Cephalosporins; Ketoglutaric Acids; Mixed Function Oxygenases; Oxidoreductases; Oxygenases | 2018 |
Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2019 |
β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Catalytic Domain; Drug Combinations; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Interspersed Repetitive Sequences | 2019 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotyping Techniques; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2020 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam | 2020 |
Carbapenems versus alternative β-lactams monotherapy or in combination for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trial.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Therapy, Combination; Febrile Neutropenia; Humans; Randomized Controlled Trials as Topic | 2020 |
Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Microbial Sensitivity Tests | 2020 |
A plethora of carbapenem resistance in
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteriophages; beta-Lactamases; beta-Lactams; Carbapenems; Cefiderocol; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Polymyxin B; Tetracyclines | 2021 |
JMM Profile: Carbapenems: a broad-spectrum antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Meropenem | 2021 |
Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cattle; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Microbial Sensitivity Tests; Quinolones; Tetracyclines | 2022 |
Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Lactams; Randomized Controlled Trials as Topic; Sepsis | 2023 |
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 2023 |
Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gammaproteobacteria; Humans; Treatment Outcome | 2023 |
Treatment of Resistant Gram-negative bacilli in children.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2023 |
5 trial(s) available for carbapenems and beta-lactams
Article | Year |
---|---|
Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.
Topics: Adult; Animals; beta-Lactams; Carbapenems; Carbon Radioisotopes; Ertapenem; Feces; Female; Humans; Lactams; Macaca mulatta; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Radioisotope Dilution Technique; Radiopharmaceuticals; Rats; Species Specificity; Tissue Distribution | 2004 |
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Middle Aged; Retrospective Studies; Sepsis; Survival Analysis; Treatment Outcome | 2016 |
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2017 |
Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Drug Resistance, Multiple; Ertapenem; Female; Humans; Italy; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Statistics, Nonparametric | 2017 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
272 other study(ies) available for carbapenems and beta-lactams
Article | Year |
---|---|
Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactams; Carbapenems; Diffusion; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Imipenem; Lactams; Liposomes; Microbial Sensitivity Tests; Molecular Weight; Permeability; Pseudomonas aeruginosa; Thienamycins | 1990 |
In-vitro activity of a new penem FCE 22101.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactamases; beta-Lactams; Carbapenems; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 1989 |
Interactions of FCE 22101 with class I beta-lactamases.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Enzyme Induction; Microbial Sensitivity Tests; Mutation | 1989 |
In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Microbial; Drug Synergism; Gentamicins; Gram-Positive Bacteria; Microbial Sensitivity Tests | 1989 |
Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Binding, Competitive; Carbapenems; Chromatography, Gel; Citrobacter; Enzyme Activation; Escherichia coli; Kinetics; Proteus vulgaris | 1984 |
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; beta-Lactams; Carbapenems; Microbial Sensitivity Tests | 1983 |
A novel beta-lactamase inhibitor, SF-2103 A produced by a Streptomyces.
Topics: beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Chemical Phenomena; Chemistry; Streptomyces | 1982 |
Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hydrogen-Ion Concentration; Hyperplasia; Kidney; Lactams; Male; Precancerous Conditions; Rats; Time Factors; Urinary Bladder; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urine | 1994 |
Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cephalosporinase; Drug Resistance, Microbial; Humans; Hydrolysis; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1993 |
Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Hydrolysis; Imipenem; Kinetics; Mutation | 1997 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Interactions; Drug Resistance, Microbial; Enzyme Induction; Hydrolysis; Imipenem; Klebsiella; Lactams; Microbial Sensitivity Tests | 1998 |
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Evaluation Studies as Topic; Gram-Negative Bacteria; Humans; Japan; Microbial Sensitivity Tests; Quality Control; Staphylococcus | 1999 |
In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Carrier Proteins; Cefdinir; Cephalosporins; Dipeptidases; Drug Stability; Escherichia coli Proteins; Hexosyltransferases; Imipenem; Lactams; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Ofloxacin; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Protein Binding; Serine-Type D-Ala-D-Ala Carboxypeptidase; Thienamycins | 1999 |
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clarithromycin; Disease Models, Animal; Helicobacter pylori; Lactams; Mice; Molecular Structure | 1999 |
In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Cephalosporins; Lactams; Microbial Sensitivity Tests | 2000 |
Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Biological Transport; Carbapenems; Carrier Proteins; Escherichia coli; Humans; Lactams; Membrane Transport Proteins; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa | 2001 |
beta-Lactam-susceptibility patterns of Plesiomonas shigelloides strains: importance of inoculum and medium.
Topics: Animals; Aztreonam; beta-Lactams; Carbapenems; Cephalosporins; Culture Media; Dogs; Humans; Microbial Sensitivity Tests; Penicillins; Plesiomonas | 2001 |
Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
Topics: Bacillus cereus; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Dose-Response Relationship, Drug; Drug Design; Hydrolysis; Models, Molecular | 2002 |
Efficient one-pot synthesis of the 2-aminocarbonylpyrrolidin-4-ylthio-containing side chain of the new broad-spectrum carbapenem antibiotic ertapenem.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Chromatography, High Pressure Liquid; Combinatorial Chemistry Techniques; Ertapenem; Lactams; Molecular Structure; Pyrrolidines; Stereoisomerism | 2002 |
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2002 |
Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase.
Topics: Aged; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Integrons; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Pseudomonas Infections; Pseudomonas putida; Urinary Tract Infections | 2002 |
Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.
Topics: Apoenzymes; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Binding Sites; Carbapenems; Computer Simulation; Crystallography, X-Ray; Enterobacter cloacae; Enzyme Inhibitors; Enzyme Stability; Klebsiella pneumoniae; Lactams; Models, Molecular; Thiazepines | 2003 |
PBP 2a mutations producing very-high-level resistance to beta-lactams.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Blotting, Western; Carbapenems; Carrier Proteins; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Hexosyltransferases; Imidazoles; Methicillin Resistance; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Mutation; Penicillin-Binding Proteins; Peptidyl Transferases; Phenotype; Plasmids; Protein Binding; Staphylococcus aureus; Transformation, Bacterial | 2004 |
Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.
Topics: Adult; Aged; Area Under Curve; beta-Lactams; Carbapenems; Creatinine; Ertapenem; Female; Half-Life; Humans; Injections, Intravenous; Lactams; Male; Spectrophotometry, Ultraviolet | 2004 |
Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Carrier Proteins; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Penicillinase; Pseudomonas aeruginosa | 2004 |
[Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Spain; Thienamycins | 2004 |
Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Carbapenems; Community-Acquired Infections; Drug Resistance, Bacterial; Ertapenem; Humans; Lactams | 2004 |
Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A beta-lactamase, GES-4, possessing a single G170S substitution in the omega-loop.
Topics: Amino Acid Sequence; Amino Acid Substitution; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephamycins; Cloning, Molecular; Conjugation, Genetic; Drug Resistance, Bacterial; Enzyme Inhibitors; Hydrolysis; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial | 2004 |
The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Colony Count, Microbial; Haemophilus Infections; Haemophilus influenzae; Humans; Lactams; Microbial Sensitivity Tests; Protein Binding; Serum Albumin; Serum Bactericidal Test | 2004 |
IMP-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa in a university hospital in the People's Republic of China.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; China; Hospitals, University; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2004 |
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rifampin; Tobramycin | 2004 |
First detection of a carbapenem-hydrolyzing metalloenzyme in an Enterobacteriaceae isolate in France.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Escherichia coli; France; Humans; Klebsiella pneumoniae; Male; Middle Aged; Penicillins; Plasmids | 2004 |
Impact of positive legionella urinary antigen test on patient management and improvement of antibiotic use.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigens, Bacterial; beta-Lactams; Carbapenems; Cephalosporins; Child, Preschool; Female; Humans; Immunoenzyme Techniques; Legionnaires' Disease; Macrolides; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity | 2004 |
Clinical experiences of bacteremia caused by metallo-beta-lactamase-producing gram-negative organisms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Child; Child, Preschool; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
Topics: beta-Lactams; Carbapenems; Culture Media, Serum-Free; Drug Resistance, Bacterial; Ertapenem; Lactams; Microbial Sensitivity Tests; Mutation; Porins; Pseudomonas aeruginosa | 2005 |
Biosynthesis of tripyrrole and beta-lactam secondary metabolites in Serratia: integration of quorum sensing with multiple new regulatory components in the control of prodigiosin and carbapenem antibiotic production.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactams; Carbapenems; Gene Expression Regulation, Bacterial; Molecular Sequence Data; Prodigiosin; Promoter Regions, Genetic; Serratia; Transcription, Genetic | 2005 |
Amino acid residues that contribute to substrate specificity of class A beta-lactamase SME-1.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Binding Sites; Carbapenems; Cefotaxime; Codon; Escherichia coli; Imipenem; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Penicillins; Substrate Specificity | 2005 |
Quantification of the carbapenem antibiotic ertapenem in human plasma by a validated liquid chromatography-mass spectrometry method.
Topics: beta-Lactams; Calibration; Carbapenems; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Kidney Failure, Chronic; Mass Spectrometry; Reference Standards; Reproducibility of Results | 2006 |
The enzymology of clavam and carbapenem biosynthesis.
Topics: Amino Acids; beta-Lactams; Carbapenems; Clavulanic Acids; Enzymes; Indicators and Reagents; Models, Molecular; Molecular Conformation; Oxidation-Reduction | 2005 |
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactams; Carbapenems; Drug Resistance, Microbial; Ertapenem; Gram-Negative Anaerobic Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inhibitory Concentration 50; Metronidazole; Microbial Sensitivity Tests | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Incidence; Length of Stay; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Taiwan | 2005 |
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
Topics: Aminoglycosides; beta-Lactam Resistance; beta-Lactams; Carbapenems; Doripenem; Drug Interactions; Gentamicins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2006 |
A theoretical proposal for the synthesis of carbapenems from 4-(2-propynyl)azetidinones promoted by [W(CO)5] as an alternative to the Ag+-assisted process.
Topics: Anti-Bacterial Agents; Azetidines; Carbapenems; Hydrolysis; Models, Chemical; Silver; Thermodynamics; Tungsten Compounds | 2006 |
Frequency and predictors of colonization of the respiratory tract by VIM-2-producing Pseudomonas aeruginosa in patients of a newly established intensive care unit.
Topics: Acute Disease; beta-Lactamases; beta-Lactams; Bronchi; Carbapenems; Carrier State; Cross Infection; Female; Genes, Bacterial; Gram-Negative Bacteria; Greece; Hospitals, General; Humans; Intensive Care Units; Male; Middle Aged; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Time Factors; Trachea; Urban Population | 2006 |
Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Spain; Thienamycins | 2006 |
In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Proteus; Sweden; Thienamycins | 2006 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Resistance, Multiple; Empiricism; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Missouri; Penicillins; Pneumonia, Bacterial; Prospective Studies; Survival Rate; Urinary Tract Infections; Ventilators, Mechanical | 2006 |
Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Humans; Klebsiella; Laboratories; Microbial Sensitivity Tests; United Kingdom | 2007 |
Is combination therapy with betalactam plus aminoglycoside (AGL) improving the outcome of nosocomial meningitis in children?
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Child, Preschool; Cross Infection; Drug Therapy, Combination; Glycopeptides; Humans; Infant; Infant, Newborn; Meningitis, Bacterial; Prognosis; Retrospective Studies; Treatment Outcome | 2007 |
Insufficient therapy for nosocomial meningitis negatively affects survival, sequellae and has social consequences.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Child, Preschool; Cross Infection; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Meningitis, Bacterial; Retrospective Studies; Treatment Failure; Vancomycin | 2007 |
Multidrug-resistant Acinetobacter baumannii, Russia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; France; Humans; Male; Microbial Sensitivity Tests; Patient Transfer; Russia | 2007 |
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
Topics: Acinetobacter; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Blotting, Southern; Carbapenems; China; Chloramphenicol; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Hospitals; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Rifampin; Sequence Analysis, DNA | 2007 |
Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Disease Outbreaks; Hospitals, University; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Polymerase Chain Reaction; Random Amplified Polymorphic DNA Technique; Sequence Analysis, DNA | 2007 |
[Bacteria isolated from perforation peritonitis and their antimicrobial susceptibilities].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intestinal Perforation; Male; Middle Aged; Peritonitis | 2007 |
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Female; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids | 2008 |
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Escherichia coli Infections; Hong Kong; Humans; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2008 |
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x.
Topics: Aminoacyltransferases; Bacterial Proteins; beta-Lactams; Carbapenems; Doripenem; Humans; Mutation; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Protein Structure, Tertiary; Streptococcus pneumoniae; United States | 2008 |
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Carbapenems; Doripenem; Escherichia coli; Escherichia coli Proteins; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Pseudomonas aeruginosa | 2008 |
Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities.
Topics: Acetylcysteine; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Diterpenes; Drug Synergism; Humans; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Streptomyces | 2008 |
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; China; Conjugation, Genetic; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Hospitals, University; Humans; Hydrolysis; Intensive Care Units; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Serratia marcescens | 2008 |
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Porins; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Turkey | 2008 |
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
Topics: Ampicillin; Bacterial Proteins; beta-Lactams; Carbapenems; Cefdinir; Cefprozil; Cephalosporins; Gene Transfer, Horizontal; Haemophilus influenzae; Mutation; Penicillin-Binding Proteins | 2008 |
Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Binding Sites; Carbapenems; Crystallization; Crystallography, X-Ray; Models, Molecular; Molecular Structure; Penicillin-Binding Proteins; Peptidyl Transferases; Protein Binding; Streptococcus pneumoniae; Thienamycins | 2008 |
In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Child; Child, Preschool; Ertapenem; Escherichia coli; Female; Hospitals, University; Humans; Infant; Infant, Newborn; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Turkey | 2008 |
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefepime; Cefuroxime; Cell Line; Cells, Cultured; Cephalosporins; Cloxacillin; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Phagocytosis; Staphylococcus aureus; Thienamycins | 2008 |
[Childhood bacterial meningitis trends in Japan from 2005 to 2006].
Topics: Adolescent; Age Distribution; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Escherichia coli; Female; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Japan; Male; Meningitis, Bacterial; Streptococcus pneumoniae; Time Factors | 2008 |
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
Topics: Adult; Anti-Bacterial Agents; Belgium; beta-Lactamases; beta-Lactams; Carbapenems; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Plasmids | 2008 |
Trends in Stenotrophomonas maltophilia bloodstream infection in relation to usage density of cephalosporins and carbapenems during 7 years.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactams; Brazil; Carbapenems; Cephalosporins; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Incidence; Stenotrophomonas maltophilia | 2008 |
Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftazidime; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Imipenem; Meropenem; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Crystallography, X-Ray; Ertapenem; Imipenem; Meropenem; Molecular Structure; Solutions; Spectrum Analysis, Raman; Thienamycins | 2008 |
Presence of the KPC carbapenemase gene in Enterobacteriaceae causing bacteremia and its correlation with in vitro carbapenem susceptibility.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Microbial Sensitivity Tests; Middle Aged; Missouri; Predictive Value of Tests | 2009 |
Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.
Topics: beta-Lactams; Carbapenems; Hospitalization; Humans; Infections; Inpatients; Randomized Controlled Trials as Topic | 2009 |
Detection of blaOXA-58 and blaOXA-23-like genes in carbapenem-susceptible Acinetobacter clinical isolates: should we be concerned?
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Humans; Ireland; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2009 |
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Carbapenems; Integrons; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Plasmids | 2009 |
Re: A VIM-1-metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Germany; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2009 |
Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Colombia; Drug Resistance, Bacterial; Greece; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Population Surveillance; Puerto Rico; Tigecycline | 2009 |
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
Topics: Algeria; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Genome, Bacterial; Hospitals, Military; Imipenem; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Phenotype | 2010 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Hospitals; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Practice Patterns, Physicians'; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2010 |
Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Crystallization; Crystallography, X-Ray; Cyclotrons; Doripenem; Ertapenem; Fourier Analysis; Hydrogen Bonding; Indicators and Reagents; Kinetics; Mass Spectrometry; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Protein Conformation | 2010 |
Detection of a common plasmid carrying blaKPC-2 in Enterobacteriaceae isolates from distinct cities in China.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; China; Electrophoresis, Gel, Pulsed-Field; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Hospitals, Urban; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multilocus Sequence Typing; Plasmids; Polymerase Chain Reaction | 2010 |
Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2010 |
Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporinase; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Hospitals, University; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Porins; Taiwan | 2010 |
OXA-134, a naturally occurring carbapenem-hydrolyzing class D beta-lactamase from Acinetobacter lwoffii.
Topics: Acinetobacter; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Sequence Homology, Amino Acid | 2010 |
Ferrier-Petasis rearrangement of 4-(vinyloxy)azetidin-2-ones: an entry to carbapenams and carbacephams.
Topics: Azetidines; Carbapenems; Cephalosporins; Molecular Conformation; Stereoisomerism | 2010 |
Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.
Topics: Age Factors; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Chi-Square Distribution; Confidence Intervals; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Risk Factors; Thienamycins | 2011 |
New Delhi metallo-beta-lactamase from traveler returning to Canada.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Canada; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; India; Male; Microbial Sensitivity Tests; Prostatitis; Pyelonephritis; Travel; Urine | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 2011 |
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Drug Utilization; Ertapenem; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Burkholderia pseudomallei; Carbapenems; Doripenem; Ertapenem; Fluoroquinolones; Humans; Melioidosis; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Case-Control Studies; Drug Utilization; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Male; Meropenem; Middle Aged; Risk Factors; Thienamycins | 2011 |
[Interpretation of the susceptibility test results in enterobacteria producing 3rd- and 4th-generation cephalosporin- or carbapenem-hydrolyzing beta-lactamases].
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Hydrolysis; Microbial Sensitivity Tests | 2011 |
Real-time TaqMan PCR for rapid detection of genes encoding five types of non-metallo- (class A and D) carbapenemases in Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Chromatography, Gel; DNA Primers; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Polymerase Chain Reaction; Taq Polymerase; Time Factors; Transition Temperature | 2011 |
Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cross Infection; Ertapenem; Hand Disinfection; Hospitals, University; Humans; Incidence; Pseudomonas aeruginosa; Pseudomonas Infections; Regression Analysis | 2011 |
Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Databases, Factual; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2011 |
Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Interactions; Ertapenem; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
[Clinical efficacy of tebipenem pivoxil treatment in children with pneumonia, who had no relief despite having administered oral beta-lactam antibiotics].
Topics: Administration, Oral; Amdinocillin Pivoxil; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child, Preschool; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Male; Pneumonia, Bacterial; Streptococcal Infections; Streptococcus pneumoniae; Treatment Failure; Treatment Outcome | 2011 |
Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; Formularies, Hospital as Topic; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; North Carolina; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2011 |
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Propensity Score; Thienamycins | 2012 |
The class A β-lactamase FTU-1 is native to Francisella tularensis.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Francisella tularensis; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data | 2012 |
First detection of blaIMI-2 gene in a clinical Escherichia coli strain.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sepsis; Sequence Analysis, DNA | 2012 |
Tn125-related acquisition of blaNDM-like genes in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA; Switzerland | 2012 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
Nosocomial outbreak of carbapenem-resistant Enterobacter cloacae highlighting the interspecies transferability of the blaOXA-48 gene in the gut flora.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Disease Outbreaks; Enterobacter cloacae; Enterobacteriaceae Infections; Gastrointestinal Tract; Gene Transfer, Horizontal; Humans; Microbial Sensitivity Tests | 2012 |
Carbapenem resistance in Elizabethkingia meningoseptica is mediated by metallo-β-lactamase BlaB.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Chryseobacterium; DNA Primers; DNA, Recombinant; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Immunoprecipitation; Real-Time Polymerase Chain Reaction; RNA, Bacterial | 2012 |
Development of carbapenem resistance during therapy for non-typhoid Salmonella infection.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Ertapenem; Feces; Female; Humans; Microbial Sensitivity Tests; Plasmids; Point Mutation; Porins; RNA, Bacterial; Salmonella Infections; Salmonella typhimurium; Urinary Tract Infections; Wound Infection | 2012 |
A high-throughput screen for the engineered production of β-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Carbon-Nitrogen Ligases; High-Throughput Screening Assays; Industrial Microbiology; Models, Molecular; Mutation; Pectobacterium carotovorum; Protein Engineering | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Logistic Models; Male; Middle Aged; Molecular Epidemiology; Multivariate Analysis; Risk Factors; Singapore; Treatment Outcome; Young Adult | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Hospitals, General; Humans; Imipenem; Italy; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2012 |
Prevalence and diversity of carbapenem-resistant bacteria in untreated drinking water in Portugal.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Colony Count, Microbial; Drinking Water; Humans; Microbial Sensitivity Tests; Phylogeny; Portugal; Prevalence | 2012 |
Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Intraabdominal Infections; Linear Models; Meropenem; Microbial Sensitivity Tests; Prevalence; Prospective Studies; Taiwan; Thienamycins | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010
Topics: Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Prevalence; Prospective Studies | 2012 |
Kinetic and crystallographic studies of extended-spectrum GES-11, GES-12, and GES-14 β-lactamases.
Topics: Acinetobacter baumannii; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Cloning, Molecular; Crystallography, X-Ray; Escherichia coli; Isoenzymes; Kinetics; Models, Molecular; Mutation; Recombinant Proteins; Structure-Activity Relationship | 2012 |
Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Drug Utilization; Ertapenem; Hospitals; Humans; Pseudomonas aeruginosa; Queensland | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
Genome sequence of OXA-48 carbapenemase-producing Klebsiella pneumoniae KpO3210.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Blood; Carbapenems; Disease Outbreaks; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2012 |
The use of UV, FT-IR and Raman spectra for the identification of the newest penem analogs: solutions based on mathematic procedure and the density functional theory.
Topics: beta-Lactams; Carbapenems; Doripenem; Models, Molecular; Quantum Theory; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Thienamycins | 2013 |
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Escherichia coli; France; Humans; India; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Polymerase Chain Reaction; Sequence Analysis, DNA | 2013 |
The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Tertiary Healthcare; Treatment Outcome | 2012 |
Comprehensive analysis of ß-lactam antibiotics including penicillins, cephalosporins, and carbapenems in poultry muscle using liquid chromatography coupled to tandem mass spectrometry.
Topics: Animals; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Chromatography, Liquid; Limit of Detection; Muscle, Skeletal; Penicillins; Poultry; Tandem Mass Spectrometry | 2013 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Complete sequence of the bla(NDM-1)-carrying plasmid pNDM-AB from Acinetobacter baumannii of food animal origin.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Gene Order; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA; Swine; Swine Diseases; Synteny | 2013 |
Rapid selection of carbapenem-resistant Pseudomonas aeruginosa by clinical concentrations of ertapenem.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Ertapenem; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Selection, Genetic | 2013 |
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Ertapenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Treatment Outcome | 2013 |
Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Kinetics; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Porins; Trans-Activators | 2013 |
A practical preparation of the key intermediate for penems and carbapenems synthesis.
Topics: Ammonia; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Lactams; Lithium; Organometallic Compounds; Oxidation-Reduction; Sodium; Stereoisomerism | 2013 |
Reply to Soman et al and Frippiat et al.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Female; Humans; Male; Penicillanic Acid; Piperacillin; Sepsis | 2013 |
Are prolonged/continuous infusions of β-lactams for all?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Female; Humans; Male; Penicillanic Acid; Piperacillin; Sepsis | 2013 |
Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Colistin; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pneumonia, Ventilator-Associated; Treatment Outcome | 2013 |
Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).
Topics: Bacteremia; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; Sequence Analysis, DNA; United States | 2013 |
Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Time Factors | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacteria; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Neoplasms | 2014 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Enzyme Inhibitors; Escherichia coli Proteins; Kinetics; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2014 |
[Analysis of the carbapenemase-producing mechanism of Enterobacteriaceae with decreased susceptibility to carbapenems].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Ertapenem; Gene Amplification; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2013 |
In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Use of outpatient parenteral antimicrobial therapy for transrectal ultrasound-guided prostate biopsy prophylaxis in the setting of community-associated multidrug-resistant Escherichia coli rectal colonization.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Hospitalization; Humans; Image-Guided Biopsy; Infusions, Parenteral; Male; Middle Aged; Outpatients; Prevalence; Prospective Studies; Prostate; Prostatitis; Rectum; Ultrasonography, Interventional | 2014 |
Biochemical analysis of metallo-β-lactamase NDM-3 from a multidrug-resistant Escherichia coli strain isolated in Japan.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Japan; Microbial Sensitivity Tests; Plasmids | 2014 |
Heteroresistance to carbapenems in New Delhi metallo-β-lactamase-1-producing isolates: a challenge for detection?
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Disease Susceptibility; Drug Resistance, Multiple; Enterobacteriaceae Infections; Ertapenem; Humans; Meropenem; Providencia; Thienamycins | 2014 |
Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests | 2014 |
Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Vietnam | 2014 |
Kinetic study of the effect of histidines 240 and 164 on TEM-149 enzyme probed by β-lactam inhibitors.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Histidine; Kinetics; Penicillins | 2014 |
Evaluation of inhibitory action of novel non β-lactam inhibitor against Klebsiella pneumoniae carbapenemase (KPC-2).
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Line; Ertapenem; HeLa Cells; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Protein Binding; Thienamycins | 2014 |
Structure of ADC-68, a novel carbapenem-hydrolyzing class C extended-spectrum β-lactamase isolated from Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Sequence Data; Protein Conformation | 2014 |
Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Ertapenem; Escherichia coli; Kinetics; Meropenem; Models, Molecular; Thienamycins | 2015 |
Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Hospitals, Teaching; Humans; Imipenem; Intensive Care Units; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Taiwan; Thienamycins | 2015 |
Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Hypoalbuminemia; Israel; Middle Aged; Prospective Studies; Risk Factors | 2015 |
[Detection of serinocarbapenemases Class A and other mechanisms of enzymatic resistance to β-lactams in enterobacteria strains with diminished susceptibility to carbapenems isolated of patients in a university hospital].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Chile; Enterobacteriaceae; Genotype; Hospitals, University; Humans; Microbial Sensitivity Tests; Phenotype | 2014 |
Profiling of β-lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39.
Topics: Amdinocillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Doripenem; Electrophoresis, Polyacrylamide Gel; Meropenem; Penicillin-Binding Proteins; Streptococcus pneumoniae; Thienamycins | 2015 |
Identification of New Natural CphA Metallo-β-Lactamases CphA4 and CphA5 in Aeromonas veronii and Aeromonas hydrophila Isolates from Municipal Sewage in Central Italy.
Topics: Aeromonas hydrophila; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Imipenem; Italy; Molecular Sequence Data; Point Mutation; Sewage; Thienamycins | 2015 |
Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Iran; Male; Urinary Tract Infections | 2015 |
Consecutive radical S-adenosylmethionine methylations form the ethyl side chain in thienamycin biosynthesis.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Catalysis; Cephalosporins; Chromatography, Liquid; Cloning, Molecular; DNA Methylation; Drug Design; Escherichia coli; Fermentation; Methylation; Penicillins; S-Adenosylmethionine; Streptomyces; Tandem Mass Spectrometry; Thienamycins; Vitamin B 12 | 2015 |
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Doripenem; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Rifampin; Thienamycins | 2015 |
Antimicrobial resistance of Pseudomonas spp. isolated from wastewater and wastewater-impacted marine coastal zone.
Topics: Anti-Infective Agents; beta-Lactams; Carbapenems; Colistin; Drug Resistance, Microbial; Environmental Monitoring; Fluoroquinolones; Microbial Sensitivity Tests; Oceans and Seas; Phylogeny; Poland; Pseudomonas; Seawater; Wastewater; Water Purification | 2015 |
Role of efflux pumps inhibitor in decreasing antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in North India.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Genotype; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Polymerase Chain Reaction; Tigecycline | 2015 |
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Ertapenem; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2016 |
Camellia sinensis Ameliorates the Efficacy of Last Line Antibiotics Against Carbapenem Resistant Escherichia coli.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactams; Camellia sinensis; Carbapenems; Colistin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Flavonoids; Free Radical Scavengers; Meropenem; Microbial Sensitivity Tests; Minocycline; Phytochemicals; Plant Extracts; Plant Leaves; Thienamycins; Tigecycline | 2016 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Kidney Transplantation; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Middle Aged; Surgical Wound Infection; Thienamycins | 2016 |
Who should receive extended infusion beta-lactam therapy?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Patient Selection; Penicillins | 2016 |
[Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Phenotype; Thienamycins; Turkey | 2016 |
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies | 2016 |
Emergence of Serratia marcescens isolates possessing carbapenem-hydrolysing β-lactamase KPC-2 from China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; China; DNA, Bacterial; Ertapenem; Female; Genotype; Hospitals; Humans; Hydrolysis; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Thienamycins; Young Adult | 2016 |
Evaluation of different pretreatment protocols to detect accurately clinical carbapenemase-producing Enterobacteriaceae by MALDI-TOF.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clinical Laboratory Techniques; Enterobacter aerogenes; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Comparison of the Modified-Hodge test, Carba NP test, and carbapenem inactivation method as screening methods for carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity; Thienamycins | 2016 |
Structural and Mutagenic Analysis of Metallo-β-Lactamase IMP-18.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Kinetics; Meropenem; Mutagens; Pseudomonas aeruginosa; Thienamycins | 2016 |
De-escalation of pivotal beta-lactam in ventilator-associated pneumonia does not impact outcome and marginally affects MDR acquisition.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Pneumonia, Ventilator-Associated; Retrospective Studies | 2016 |
1,3-Dipolar cycloaddition of a cyclic nitrone derived from 2-deoxy-D-ribose to α,β-unsaturated lactones: An entry to carbapenem antibiotics.
Topics: beta-Lactams; Carbapenems; Cycloaddition Reaction; Deoxyribose; Lactones; Molecular Structure; Nitrogen Oxides; Stereoisomerism | 2016 |
Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Gentamicins; Hospitals; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Serbia; Thienamycins | 2016 |
Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gentamicins; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Tigecycline; Vietnam | 2016 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Hospitals; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Thienamycins | 2016 |
Transposition of Tn125 Encoding the NDM-1 Carbapenemase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Bacterial Proteins; Base Composition; Base Sequence; beta-Lactamases; beta-Lactams; Carbapenems; DNA Transposable Elements; Humans; Microbial Sensitivity Tests | 2016 |
Bulgecin A as a β-lactam enhancer for carbapenem-resistant
Topics: Acetylglucosamine; Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enzyme Inhibitors; Proline; Pseudomonas aeruginosa | 2016 |
Expanded Substrate Activity of OXA-24/40 in Carbapenem-Resistant Acinetobacter baumannii Involves Enhanced Binding Loop Flexibility.
Topics: Acinetobacter baumannii; Amino Acid Motifs; Amino Acid Sequence; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Magnetic Resonance Spectroscopy; Models, Molecular; Mutation; Pliability; Protein Binding; Protein Domains; Protein Structure, Secondary; Substrate Specificity | 2016 |
Phenotypic and molecular detection of the bla
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Brazil; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Hospitals; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; Polymerase Chain Reaction; Pseudomonas aeruginosa | 2016 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Binding and processing of β-lactam antibiotics by the transpeptidase Ldt
Topics: beta-Lactams; Carbapenems; Crystallography, X-Ray; Kinetics; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Protein Conformation; Tuberculosis | 2017 |
E152A substitution drastically affects NDM-5 activity.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Drug Resistance, Multiple, Bacterial; Escherichia coli; Glutamic Acid; Hydrolysis; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Mutation | 2017 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefoxitin; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Ertapenem; Escherichia coli; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Turkey; Urinary Tract Infections | 2017 |
Occurrence of bla
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Conjugation, Genetic; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; India; Plasmids | 2017 |
Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Catechin; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Phytotherapy; Plant Extracts | 2017 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Thienamycins | 2017 |
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Gene Transfer, Horizontal; Humans; Imipenem; Klebsiella; Meropenem; Plasmids; Thienamycins; United Kingdom | 2017 |
Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.
Topics: beta-Lactams; Carbapenems; Ertapenem; Imipenem; Meropenem; Molecular Dynamics Simulation; Mycobacterium tuberculosis; Principal Component Analysis; Thienamycins | 2017 |
In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Child; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter; Enterobacteriaceae Infections; Greece; Hospitals, University; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tigecycline | 2017 |
Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase Ldt
Topics: beta-Lactams; Carbapenems; Crystallography, X-Ray; Drug Design; Mycobacterium tuberculosis; Peptidyl Transferases; Protein Binding; Thienamycins | 2017 |
Ldt
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Crystallography, X-Ray; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Mycobacterium avium Complex; Peptidyl Transferases; Sequence Analysis, DNA | 2017 |
Drug allergy evaluation for betalactam hypersensitivity: Cross-reactivity with cephalosporines, carbapenems and negative predictive value.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Child; Cross Reactions; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Penicillins; Predictive Value of Tests; Skin Tests | 2018 |
Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cohort Studies; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Neutropenia | 2017 |
Cumulative Effect of an Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle on Early Streamlining of Antimicrobial Therapy in Gram-Negative Bloodstream Infections.
Topics: Adolescent; Anti-Bacterial Agents; Antimicrobial Stewardship; Bacteremia; beta-Lactams; Blood Culture; Carbapenems; Gram-Negative Bacteria; Humans; Prospective Studies | 2017 |
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Dogs; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Mice; Models, Molecular; Penicillin-Binding Proteins; Rats; Sulbactam | 2017 |
Thiol-Containing Metallo-β-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefoperazone; Drug Resistance, Bacterial; Gram-Negative Bacteria; Meropenem; Molecular Structure; Sulfhydryl Compounds; Thienamycins | 2017 |
Reducing Carbapenem Exposure: Extended-Spectrum β-Lactamase Catheter-Associated Urinary Tract Infection Management.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Female; Humans; Male; Middle Aged; United States; Urinary Tract Infections | 2017 |
The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum β-lactamase producing Escherichia coli.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Pyelonephritis; Republic of Korea; Retrospective Studies; Risk Factors; Treatment Outcome | 2018 |
Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants.
Topics: Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Coordination Complexes; Copper; Ertapenem; Escherichia coli; Humans; Ions; Meropenem; Microbial Sensitivity Tests; Urinary Tract Infections | 2018 |
A nitrocefin disc supplemented with ertapenem for rapid screening of carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Microbial Sensitivity Tests; Sensitivity and Specificity | 2018 |
Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Electrophoresis, Polyacrylamide Gel; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutation; Porins | 2018 |
Novel variant NDM-11 and other NDM-1 variants in multidrug-resistant Escherichia coli from South India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Genetic Variation; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Plasmids; Snake Bites; Wound Infection | 2018 |
Phylogenomic Analysis of β-Lactamase in Archaea and Bacteria Enables the Identification of Putative New Members.
Topics: Anti-Bacterial Agents; Archaea; Bacteria; beta-Lactamases; beta-Lactams; Carbapenems; Humans; Metagenomics; Phylogeny | 2018 |
Rapid detection of carbapenemase activity of Enterobacteriaceae isolated from positive blood cultures by MALDI-TOF MS.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; beta-Lactams; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Ertapenem; Humans; Hydrolysis; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Inferring Antimicrobial Resistance from Pathogen Genomes in KEGG.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Databases, Genetic; Drug Resistance, Bacterial; Genome, Bacterial; Phylogeny | 2018 |
Genetic and Biochemical Characterization of OXA-535, a Distantly Related OXA-48-Like β-Lactamase.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Chromosomes, Bacterial; Microbial Sensitivity Tests; Plasmids; Shewanella | 2018 |
Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Case-Control Studies; Cefoperazone; China; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Sulbactam | 2018 |
Antibiotics associated with acquisition of carbapenem-resistant Pseudomonas aeruginosa in ICUs: a multicentre nested case-case-control study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Female; Hospitalization; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Prospective Studies; Pseudomonas aeruginosa; Risk Factors | 2019 |
Novel Antibiotics in the Treatment of Urinary Tract Infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Clinical Trials as Topic; Cystitis; Drug Resistance, Bacterial; Drug Therapy, Combination; Drug Utilization; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Iatrogenic Disease; Tetracyclines; Urinary Tract Infections | 2019 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Boronic Acids; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2019 |
Evaluation of Susceptibilities to Carbapenems and Faropenem Against Cephalosporin-Resistant Neisseria gonorrhoeae Clinical Isolates with penA Mosaic Alleles.
Topics: Alleles; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Carbapenems; Cephalosporin Resistance; Cephalosporins; Humans; Male; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae | 2019 |
Modeling Ertapenem: the impact of body mass index on distribution of the antibiotic in the body.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Body Mass Index; Body Weight; Carbapenems; Computer Simulation; Drug Administration Schedule; Ertapenem; Female; Humans; Male; Models, Theoretical; Obesity; Thinness | 2019 |
Anti-ESBL investigation of chitosan/silver nanocomposites against carbapenem resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Chitosan; Drug Resistance, Bacterial; Metal Nanoparticles; Microbial Sensitivity Tests; Nanocomposites; Pseudomonas aeruginosa; Silver | 2019 |
Comparison of adhesin genes expression among Klebsiella oxytoca ESBL-non-producers in planktonic and biofilm mode of growth, and imipenem sublethal exposure.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Biofilms; Carbapenems; Gene Expression Regulation, Bacterial; Genes, Bacterial; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Microbial Sensitivity Tests; Phenotype | 2019 |
Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307.
Topics: Argentina; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Multilocus Sequence Typing; Plasmids | 2019 |
Identification of Mutations in the
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Escherichia coli Proteins; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase | 2019 |
Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Citrobacter freundii; Enterobacter cloacae; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Serratia marcescens | 2019 |
Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Computer Simulation; Continuous Renal Replacement Therapy; Critical Illness; Dose-Response Relationship, Drug; Humans; Models, Biological; Monte Carlo Method | 2019 |
New Trimodal Phenotypic Reporter of Extended-Spectrum β-Lactamase Activity.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; beta-Lactams; Biosensing Techniques; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Oxazines; Sulfides | 2019 |
Direct medical costs of urinary tract infections by Gram-negative bacilli resistant to beta-lactams in a tertiary care hospital in Medellín, Colombia
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cephalosporins; Cohort Studies; Colombia; Cross Infection; Diagnostic Imaging; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Health Expenditures; Hospitalization; Hospitals, Urban; Humans; Male; Middle Aged; Tertiary Care Centers; Urinary Tract Infections | 2019 |
Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Japan; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Multilocus Sequence Typing; Plasmids; Whole Genome Sequencing | 2020 |
Higher rates of carbapenem-related seizures in older hospitalised adults.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Logistic Models; Male; Meropenem; Seizures; Singapore | 2020 |
Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Porins | 2020 |
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cell Membrane Permeability; Enterobacter cloacae; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2020 |
Structure and Molecular Recognition Mechanism of IMP-13 Metallo-β-Lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems | 2020 |
Impact of removing ESBL designation from culture reports on the selection of antibiotics for the treatment of infections associated with ESBL-producing organisms.
Topics: Academic Medical Centers; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Utilization; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Philadelphia; Retrospective Studies | 2020 |
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Pharmaceutical Preparations | 2020 |
The Effect of Beta-lactam Allergy Status on the Rate of Surgical Site Infections: A Retrospective Cohort Study.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactams; Carbapenems; Cefazolin; Cephalosporins; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Penicillins; Retrospective Studies; Risk Factors; Surgical Wound Infection | 2022 |
4-(
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Biocatalysis; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Thiones; Triazoles | 2020 |
Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Immunoglobulin G; Meropenem; Monobactams; Penicillins; Skin Tests | 2020 |
The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Mice; Microbial Sensitivity Tests | 2021 |
Risk comparison of beta-lactam-induced anaphylaxis: Therapeutic stratification analysis in a Vietnamese pharmacovigilance database.
Topics: Age Factors; Anaphylaxis; Anti-Bacterial Agents; Asian People; beta-Lactams; Carbapenems; Cephalosporins; Drug Therapy, Combination; Humans; Penicillins; Pharmacovigilance; Risk Factors; Sex Factors; Vietnam | 2021 |
Click and Release Chemistry for Activity-Based Purification of β-Lactam Targets.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Click Chemistry; Penicillin-Binding Proteins; Peptidoglycan; Peptidyl Transferases | 2021 |
Biochemical characterization of OXA-244, an emerging OXA-48 variant with reduced β-lactam hydrolytic activity.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Escherichia coli Proteins; Hydrolysis; Microbial Sensitivity Tests | 2021 |
Role of AmpG in the resistance to β-lactam agents, including cephalosporins and carbapenems: candidate for a novel antimicrobial target.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cephalosporins; CRISPR-Cas Systems; Democratic People's Republic of Korea; DNA Transposable Elements; Gene Expression Regulation, Bacterial; Gene Knockout Techniques; Humans; Klebsiella pneumoniae; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutagenesis; Sequence Alignment | 2021 |
Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Cyclooctanes; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutation; Porins | 2021 |
A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2021 |
Probable Encephalopathy and Spasticity in a Multiple Sclerosis Patient Following Carbapenem Administration: A Case Report and Brief Literature Review.
Topics: Anti-Bacterial Agents; beta-Lactams; Brain Diseases; Carbapenems; Female; Humans; Middle Aged; Multiple Sclerosis | 2023 |
Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; COVID-19; Drug Resistance, Multiple, Bacterial; Humans; Mice; Microbial Sensitivity Tests; Pandemics; Pneumonia, Ventilator-Associated; Tetracycline; Tigecycline; Zinc | 2022 |
Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relat
Topics: Amino Acids; Animals; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Mice; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Permeability | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Featured Article Editorial: Discovery of a Tricyclic β-Lactam Active against Carbapenem-Resistant Enterobacterales.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Microbial Sensitivity Tests | 2022 |
Prevalence and molecular characterization of foodborne and human-derived Salmonella strains for resistance to critically important antibiotics.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cattle; Cephalosporins; Ciprofloxacin; Colistin; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Monobactams; Prevalence; Rabbits; Salmonella; Salmonella enterica; Tetracyclines | 2022 |
Uncovering Beta-Lactam Susceptibility Patterns in Clinical Isolates of Mycobacterium tuberculosis through Whole-Genome Sequencing.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Peptidoglycan; Tuberculosis | 2022 |
QM/MM Simulations Reveal the Determinants of Carbapenemase Activity in Class A β-Lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Gram-Negative Bacteria; Molecular Dynamics Simulation | 2022 |
Using Culture-Enriched Phenotypic Metagenomics for Targeted High-Throughput Monitoring of the Clinically Important Fraction of the β-Lactam Resistome.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Metagenomics; Microbial Sensitivity Tests; Water Purification | 2022 |
Genomic characterization of BKC-1-producing Klebsiella pneumoniae strain belonging to high-risk clone sequence type 11 isolated from a river in Brazil.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Brazil; Carbapenems; Clone Cells; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genomics; Humans; Klebsiella; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Polymyxins; Rivers; Siderophores; Type VI Secretion Systems | 2022 |
Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
Topics: Aminoglycosides; Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Cross Infection; Delivery of Health Care; Enterobacteriaceae; Enterobacteriaceae Infections; France; Humans; Nitrofurantoin; Ofloxacin; Penicillins; Urinary Tract Infections | 2022 |
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefuroxime; Humans; Lactams; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium abscessus | 2022 |
Proteomics profiling of ertapenem challenged major porin deficient carbapenem-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Antioxidants; ATP-Binding Cassette Transporters; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Proteomics | 2022 |
Beta-lactam hypersensitivity diagnosis in ambulatory and hospitalized settings require different approaches.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Penicillins; Skin Tests | 2023 |
Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Data Mining; Molecular Docking Simulation; Monobactams; Penicillins; Tazobactam | 2022 |
Effects of reported beta-lactam allergies on pneumonia outcomes in lung transplant recipients.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Clostridium Infections; Drug Hypersensitivity; Fluoroquinolones; Humans; Hypersensitivity; Lung; Pneumonia; Retrospective Studies; Transplant Recipients | 2022 |
Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neurotoxicity Syndromes; Renal Dialysis; Renal Insufficiency, Chronic | 2022 |
Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftriaxone; Enterobacteriaceae; Enterobacteriaceae Infections; Gammaproteobacteria; Humans; Lactams; Retrospective Studies; Urinary Tract Infections | 2023 |
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans | 2023 |
A conserved zinc-binding site in
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Binding Sites; Carbapenems; Cell Shape; Chelating Agents; Penicillin-Binding Proteins; Peptidyl Transferases; Zinc | 2023 |
Interactions of hydrolyzed β-lactams with the L1 metallo-β-lactamase: Crystallography supports stereoselective binding of cephem/carbapenem products.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Crystallography; Gram-Negative Bacterial Infections; Humans; Kinetics; Stenotrophomonas maltophilia | 2023 |
Phenotypic and molecular characterization of beta-lactam resistant Multidrug-resistant Enterobacterales isolated from patients attending six hospitals in Northern Nigeria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Escherichia coli; Hospitals; Humans; Microbial Sensitivity Tests; Nigeria | 2023 |
Antibiotic Consumption During the Coronavirus Disease 2019 Pandemic and Emergence of Carbapenemase-Producing Klebsiella pneumoniae Lineages Among Inpatients in a Chilean Hospital: A Time-Series Study and Phylogenomic Analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chile; Colistin; COVID-19; Hospitals; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pandemics; Phylogeny | 2023 |